drugset / Trial / NCT00823875
Study of Cilostazol and Probucol Alone and in Combination on Atherosclerosis Related Biomarker---atherosclerosis Cerebral Infarction Patient as Study Subject
RandomizedParallel-groupOpen-labelTreatment
Summary
Randomized, control, open label, multicentre clinical study. The patient who are in accordance with subject inclusion and exclusion criteria will be randomized to A group: Routine treatment B group: Routine treatment+ Cilostazol; C group : Routine treatment + Probucol; D group: Routine treatment+ Cilostazol+ Probucol .
Timeline
- Start
- 2009-03
- Primary completion
- 2009-12
- Completion
- 2010-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cilostazol | Small molecule | 100 mg | Oral |
| Subject | Probucol | Small molecule | 250 mg | Oral |